All In Biotech

Drug Trial Radar · NCT00359567

Comparative Study of Palonosetron With Granisetron as a Control in Patients Receiving Highly Emetogenic Chemotherapy

Comparative Study of Intravenous Single Doses of Palonosetron (PALO) With Granisetron Hydrochloride as a Control in Patients Receiving Highly Emetogenic Chemotherapy

Last checked: Nov 20, 2026Latest source record: Jul 7, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,140 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,140

Planned (sponsor's estimate)

Start

Jul 2006

Primary completion

May 2007

Study completion Aug 2007

Sponsor

Lead sponsor
Taiho Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Aug 2, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare palonosetron with granisetron hydrochloride as a control in the efficacy of intravenous single dose in preventing acute and delayed gastro-intestinal disorders, such as nausea and vomiting induced by highly emetogenic chemotherapy.

Conditions

  • Chemotherapy-Induced Nausea and Vomiting

Interventions

  • palonosetronDrug

    intravenous injections of 0.75 mg palonosetron (5 mL) and then granisetron placebo before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.

  • granisetron hydrochlorideDrug

    intravenous injections of palonosetron placebo and then 40μg/kg granisetron hydrochloride before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete response (CR: no emetic episodes and no rescue medication) rate in acute and delayed nausea and vomiting

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center

    5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.